CA
NZ
UK
AU
IND
US
Gyre Therapeutics (NASDAQ: GYRE) announced the appointment of three new directors effective Aug. 1, 2026, bringing fresh scientific and operational expertise to its board. The three appointees, Chief Scientific Officer Dr.
The sale, executed under a prearranged trading plan, comes as Precigen’s orphan drug status for Papzimeos grants market exclusivity through August 2032, a catalyst that has propelled the stock to multi-year highs. While insider sales under 10b5-1 plans are often routine, the timing, amid …
Bio-Path Holdings has raised capital through two unregistered share sales under its Regulation A offering, leaving additional funding capacity as it scrambles to fund a strategic pivot that now includes crypto investments and AI-driven drug trials. The company issued 466,100 common shares on April …
Entera Bio Ltd. has cleared a key corporate milestone, obtaining shareholder consent to more than double its authorized ordinary share count. The vote, conducted at the 2026 annual meeting, also endorsed a one‑time augmentation of its equity incentive pool and introduced three additional directors …
Getinge AB (OTC: GNGBY) posted earnings per share of $1.80 for the quarter ended March 31, surpassing the $1.70 consensus. The result arrived as the stock lingered at $20.05, reflecting a 9.3% decline since the start of the year while remaining unchanged over the …
Calidi Biotherapeutics announced a relocation that trims its overhead by an estimated $1.1 million each year. The move shifts the biotech firm into a 9,038‑square‑foot laboratory and office suite, with the lease term set for a period beginning Oct 1 2026. The cost savings …
Today's session showed a clear split within the healthcare and pharma-distribution complex. Oscar Health (NYSE: OSCR) and Astrana Health (NASDAQ: ASTH) both suffered sharp single-day reversals after explosive multi-month rallies, each breaking or testing their steep ascending trendlines. McKesson (NYSE: MCK) moved the opposite …
McKesson Corp. (NYSE: MCK) posted diluted earnings of $11.69 for the quarter ended March 31 2026, narrowly topping the $11.68 consensus. The 16% year‑over‑year increase lifted the stock to $828.47 in the latest trade, a 4.0% rise that pushes the market value to roughly …
The company also disclosed a strategic alliance with Philips that unlocks hospital access across more than 70 countries. Revenue momentum was bolstered, yet the U.S. market continued to pose headwinds, prompting management to tighten cost discipline.
Slate Medicines has strengthened its leadership with the appointment of Mark W. Hahn, a biotech executive whose track record includes guiding Verona Pharma through a $10 billion acquisition by Merck. The move signals a strategic push to accelerate the development of migraine treatments, a …
Please wait processing your request...